Skip to main content

Advertisement

Table 4 Comparison of the sample sizes and joinpoint estimates, presented with 95% confidence intervals, for all analyses

From: What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink

  Probable AD Any AD Any dementia
Source Main analysis Additional file 3 Additional file 3
Diagnoses Probable AD Probable AD Possible AD Probable AD Possible AD Non-AD and mixed dementias
AChE inhibitors Eligible: 10,456 Treated: 5019 Joinpoint 1: Oct 2012 (Sep 2011–Apr 2013) Joinpoint 2: May 2013 (Nov 2012–Apr 2014) Eligible: 21,342 Treated: 6449 Joinpoint 1: Jun 1999 (Apr 1998–Dec 2000) Joinpoint 2: Jun 2001 (Sep 2000–Mar 2002) Eligible: 38,650 Treated: 9896 Joinpoint 1: Aug 2000 (Jun 1998–Nov 2000) Joinpoint 2: Jan 2001 (Sep 2000–Nov 2001)
NMDA receptor antagonists Eligible: 9964 Treated: 1052 Joinpoint 1: Mar 2011 (Aug 2010–Apr 2011) Joinpoint 2: Jun 2011 (Apr 2011–Nov 2011) Eligible: 18,930 Treated: 1309 Joinpoint 1: Sep 2010 (Dec 2009–Apr 2011) Joinpoint 2: Nov 2011 (Apr 2011–Mar 2012) Eligible: 35,625 Treated: 1961 Joinpoint 1: Aug 2010 (Nov 2009–Dec 2010) Joinpoint 2: Nov 2011 (Aug 2011–Mar 2012)
  1. AChE Acetylcholinesterase, AD Alzheimer’s disease, NMDA N-methyl-d-aspartate